Person

Katarzyna Jóźwiak

Dr. Jóźwiak
Title:Dr.
Current position:Scientific personnel
Specialist field:Biometrie und Registerforschung
Office address:

Institut für Biometrie und Registerforschung
Fehrbelliner Str. 38
16816 Neuruppin

Office phone number:+49 3391 39 14584
Office email:katarzyna.jozwiak@mhb-fontane.de
 
Curriculum Vitae

Dr. Katarzyna Jóźwiak obtained a Master's degree in Applied Mathematics from Delft University, The Netherlands, in 2008, and in Econometrics and Computer Science from the University of Zielona Góra, Poland, in 2009. As a graduate student in Applied Statistics at Utrecht University, The Netherlands, she investigated optimal designs of trials with discrete-time survival endpoints and completed her PhD in 2013. After a brief period as software developer at Utrecht University, Dr. Jóźwiak worked at the Netherlands Cancer Institute in Amsterdam (The Netherlands), till June 2019 where she collaborated as a senior statistician with clinicians and other researchers of the Institute and the Antoni van Leeuwenhoek hospital. Since 2019, Dr. Jóźwiak is a senior statistician at the Institute of Biostatistics and Registry Research. For a complete CV, click here.

Publications

Van der Willik KD, Hauptmann M, Jóźwiak K, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram A, Schagen SB. Trajectories of cognitive performance prior to cancer diagnosis: a population-based study. In press.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, Van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res 2019; 25(14): 4351–4362. 

Krul IMK, Opstal-Van Winden AWJ, Janus CPM, Daniels LA, Appelman Y, Maas AHEM, De Vries S, Jóźwiak K, Aleman BMP, Van Leeuwen F. Cardiovascular disease risk after treatment-induced premature ovarian insuffciency in female survivors of Hodgkin lymphoma. J Am Coll Cardiol 2018; 72(25): 3374–3375.

Groot HJ, Lubberts S, De Wit R, Witjes JA, Kerst JM, De Jong IJ, Groenewegen G, Van den Eertwegh AJM, Poortmans PM, Klumpen H, Van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Incrocci L, Van den Bergh ACM, Jóźwiak K, Van den Belt-Dusebout AW, Horenblas S, Gietema JA, Van Leeuwen FE, Schaapveld M. Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era. J Clin Oncol 2018; 36(4): 2504–2513.

Van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, Van Santbrink EJ, Van der Westerlaken LA, Cohlen BJ, Braat DD, Smeenk JM, Land JA, Goddijn M, Van Golde RJ, Van Rumste MM, Schats R, Jóźwiak K, Hauptmann M, Rookus MA, Burger CW, Van Leeuwen FE. Association between ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 2016; 316(3): 300–312.

Theunissen EA, Zuur CL, Jóźwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, Van der Baan S, De Boer JP, Dreschler WA, Balm AJ. Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015; 141(9): 810–815.